Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Albumins*/administration & dosage ; Albumins*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/administration & dosage ; Deoxycytidine*/therapeutic use ; Gemcitabine* ; Paclitaxel*/administration & dosage ; Paclitaxel*/therapeutic use ; Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/pathology ; Simvastatin*/administration & dosage ; Simvastatin*/therapeutic use ; Valproic Acid*/therapeutic use ; Valproic Acid*/administration & dosage; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Carcinoma, Pancreatic Ductal/drug therapy ; Carcinoma, Pancreatic Ductal/pathology ; Drug Repositioning/methods ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic ; Clinical Trials, Phase II as Topic
    • Abstract:
      Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) patients have very poor prognosis highlighting the urgent need of novel treatments. In this regard, repurposing non-oncology already-approved drugs might be an attractive strategy to offer more-effective treatment easily tested in clinical trials. Accumulating evidence suggests that epigenetic deregulation is a hallmark of cancer contributing to treatment resistance in several solid tumors, including PDAC. Histone deacetylase inhibitors (HDACi) are epigenetic drugs we have investigated preclinically and clinically as anticancer agents. Valproic acid (VPA) is a generic low-cost anticonvulsant and mood stabilizer with HDAC inhibitory activity, and anticancer properties also demonstrated in PDAC models. Statins use was reported to be associated with lower mortality risk in patients with pancreatic cancer and statins have been shown to have a direct antitumor effect when used alone or in combination therapy. We recently showed capability of VPA/Simvastatin (SIM) combination to potentiate the antitumor activity of gemcitabine/nab-paclitaxel in vitro and in vivo PDAC preclinical models.
      Methods/design: VESPA is a patient-centric open label randomized multicenter phase-II investigator-initiated trial, evaluating the feasibility, safety, and efficacy of VPA/SIM plus first line gemcitabine/nab-paclitaxel-based regimens (AG or PAXG) (experimental arm) versus chemotherapy alone (standard arm) in mPDAC patients. The study involves Italian and Spanish oncology centers and includes an initial 6-patients safety run-in-phase. A sample size of 240 patients (120 for each arm) was calculated under the hypothesis that the addition of VPA/SIM to gemcitabine and nab-paclitaxel-based regimens may extend progression free survival from 6 to 9 months in the experimental arm. Secondary endpoints are overall survival, response rate, disease control rate, duration of response, CA 19.9 reduction, toxicity, and quality of life. The study includes a patient engagement plan and complementary biomarkers studies on tumor and blood samples.
      Conclusions: VESPA is the first trial evaluating efficacy and safety of two repurposed drugs in oncology such as VPA and SIM, in combination with standard chemotherapy, with the aim of improving mPDAC survival. The study is ongoing. Enrollment started in June 2023 and a total of 63 patients have been enrolled as of June 2024.
      Trial Registration: EudraCT number: 2022-004154-63; ClinicalTrials.gov identifier NCT05821556, posted 2023/04/20.
      (© 2024. The Author(s).)
    • References:
      Front Oncol. 2021 Jun 23;11:682872. (PMID: 34249730)
      Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
      Recent Pat Anticancer Drug Discov. 2018;13(2):184-200. (PMID: 29189178)
      Int J Cancer. 2012 Oct 15;131(8):1951-62. (PMID: 22287227)
      Invest New Drugs. 2019 Feb;37(1):109-117. (PMID: 29995287)
      Front Oncol. 2023 Jan 11;12:1110104. (PMID: 36713567)
      Int J Mol Sci. 2019 Feb 05;20(3):. (PMID: 30764482)
      Target Oncol. 2015 Dec;10(4):575-81. (PMID: 25940934)
      Semin Oncol. 2021 Feb;48(1):47-56. (PMID: 33674067)
      J Clin Oncol. 2005 Oct 1;23(28):7199-206. (PMID: 16192604)
      Front Oncol. 2021 May 24;11:682911. (PMID: 34109128)
      Carcinogenesis. 2020 Jul 14;41(7):927-939. (PMID: 31584613)
      Ther Adv Med Oncol. 2020 Aug 11;12:1758835920929589. (PMID: 32849914)
      Mol Cancer. 2005 Jul 07;4(1):22. (PMID: 16001982)
      Cancer Treat Rev. 2008 May;34(3):206-22. (PMID: 18226465)
      J Exp Clin Cancer Res. 2020 Oct 8;39(1):213. (PMID: 33032653)
      Onco Targets Ther. 2019 Aug 19;12:6665-6684. (PMID: 31692495)
      PLoS One. 2015 Jul 30;10(7):e0134594. (PMID: 26226632)
      Int J Mol Sci. 2020 Jun 08;21(11):. (PMID: 32521716)
      Front Cell Dev Biol. 2020 Aug 17;8:732. (PMID: 33015030)
      Oncologist. 2007 Oct;12(10):1247-52. (PMID: 17962618)
      Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):390-9. (PMID: 23838105)
      J Biomed Biotechnol. 2010;2010:. (PMID: 20798865)
      Immunology. 2018 May;154(1):69-75. (PMID: 29392731)
      Br J Cancer. 2007 Jul 16;97(2):177-82. (PMID: 17579623)
      J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
      BMC Cancer. 2016 Nov 25;16(1):918. (PMID: 27884140)
      Cancers (Basel). 2021 Apr 04;13(7):. (PMID: 33916610)
      J Clin Oncol. 2007 May 20;25(15):1979-85. (PMID: 17513804)
      Cancer Res. 2016 May 1;76(9):2525-39. (PMID: 26980767)
      BMC Cancer. 2014 Nov 24;14:875. (PMID: 25421252)
      Clin Cancer Res. 2009 Apr 1;15(7):2488-96. (PMID: 19318486)
      N Engl J Med. 1996 Jan 18;334(3):168-75. (PMID: 8531974)
      Mol Carcinog. 2013 Sep;52(9):739-50. (PMID: 22549877)
      Cell Biosci. 2019 Jun 18;9:50. (PMID: 31244991)
      Cancers (Basel). 2021 Jun 02;13(11):. (PMID: 34199435)
      Cancer Discov. 2015 May;5(5):OF4. (PMID: 25802326)
      PLoS One. 2006 Dec 20;1:e98. (PMID: 17183730)
      J Exp Clin Cancer Res. 2019 Apr 8;38(1):150. (PMID: 30961642)
      Nat Commun. 2019 Aug 28;10(1):3875. (PMID: 31462645)
      Clin Cancer Res. 2015 Jun 15;21(12):2666-70. (PMID: 25802282)
      Clin Pharmacol Ther. 2010 Feb;87(2):166-74. (PMID: 20010556)
      Expert Rev Hematol. 2013 Aug;6(4):351-9. (PMID: 23991922)
      Onco Targets Ther. 2021 Jun 21;14:3803-3812. (PMID: 34188488)
      Cancer Manag Res. 2020 Jun 17;12:4645-4665. (PMID: 32606957)
      Nat Rev Clin Oncol. 2011 Mar 30;8(4):189-90. (PMID: 21448176)
      J Clin Med. 2019 Jun 26;8(7):. (PMID: 31247937)
      J Exp Clin Cancer Res. 2022 Mar 3;41(1):83. (PMID: 35241126)
      Metabolites. 2016 Mar 02;6(1):. (PMID: 26950159)
      Lancet. 2023 Oct 7;402(10409):1272-1281. (PMID: 37708904)
      J Natl Cancer Inst. 2016 Dec 31;109(5):. (PMID: 28040693)
      Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79. (PMID: 21330149)
      Immunotherapy. 2016 Jun;8(6):705-19. (PMID: 27197539)
      Cancer Lett. 2018 Dec 28;439:101-112. (PMID: 30290209)
      N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
      Lancet Gastroenterol Hepatol. 2018 Oct;3(10):691-697. (PMID: 30220407)
    • Grant Information:
      101057442 European Union's Horizon Europe research and innovation; RF-2021-12371995 Ministero della Salute
    • Contributed Indexing:
      Keywords: Drug repurposing; Gemcitabine, nab-paclitaxel; Pancreatic cancer; Simvastatin; Valproic acid
    • Molecular Sequence:
      ClinicalTrials.gov NCT05821556
    • Accession Number:
      0 (130-nm albumin-bound paclitaxel)
      0 (Albumins)
      0W860991D6 (Deoxycytidine)
      0 (Gemcitabine)
      P88XT4IS4D (Paclitaxel)
      AGG2FN16EV (Simvastatin)
      614OI1Z5WI (Valproic Acid)
    • Publication Date:
      Date Created: 20240919 Date Completed: 20240920 Latest Revision: 20241018
    • Publication Date:
      20241019
    • Accession Number:
      PMC11414294
    • Accession Number:
      10.1186/s12885-024-12936-w
    • Accession Number:
      39300376